<DOC>
	<DOCNO>NCT00245388</DOCNO>
	<brief_summary>This randomize , double-blind , dose-ranging , placebo-controlled trial determine lipid-lowering efficacy safety BMS-298585 ( muraglitazar ) alone combination pravastatin subject mixed dyslipidemia .</brief_summary>
	<brief_title>Efficacy Safety BMS-298585 Alone Combination With Pravastatin Subjects With Mixed Dyslipidemia</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Pravastatin</mesh_term>
	<criteria>Nondiabetics Serum TG &gt; 150 mg/dL &lt; = 600 mg/dL Serum LDLC &gt; 130 mg/dL Type 1 type 2 diabetic Fasting plasma glucose &gt; 126 mg/dL Treatment lipidlowering drug , unless withdraw within follow time frame prior first qualify lipid determination ( Week 2 ) : Niacin bileacid bind agent HMG CoA reductase inhibitor : 8 week Fibrates : 8 week Probucol : 1 year History active liver disease and/or history thiazolidinedionerelated ( troglitazone , rosiglitazone , pioglitazone ) liver abnormality , hepatic dysfunction , jaundice</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Mixed Dyslipidemia</keyword>
</DOC>